Eysuvis positioned as short-term solution for dry eye flares

Eysuvis positioned as short-term solution for dry eye flares

[ad_1]


We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Todd Bazemore, chief operating officer at Kala Pharmaceuticals, offers a company update, including the recent approval of Eysuvis (loteprednol) for dry eye disease signs and symptoms.

[ad_2]

Source link